tiprankstipranks
Trending News
More News >
Terminalcare Support Institute, Inc. (JP:7362)
:7362
Japanese Market
Advertisement

Terminalcare Support Institute, Inc. (7362) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7362

Terminalcare Support Institute, Inc.

(7362)

Select Model
Select Model
Select Model
Neutral 64 (OpenAI - 4o)
Rating:64Neutral
Price Target:
¥883.00
▲(7.55% Upside)
The overall score reflects solid financial performance with growth in revenues and stable gross margins, but challenges in profitability and rising debt levels are concerns. Technical analysis indicates bearish momentum, while valuation is reasonable. The absence of earnings call data and corporate events limits further insights.

Terminalcare Support Institute, Inc. (7362) vs. iShares MSCI Japan ETF (EWJ)

Terminalcare Support Institute, Inc. Business Overview & Revenue Model

Company DescriptionTerminalcare Support Institute Inc. provides home-visit care, preventive care, home-care support, and home-visit nursing services in Japan. It also offers housing for the elderly services. The company was founded in 2010 and is headquartered in Kyoto, Japan.
How the Company Makes MoneyTerminalcare Support Institute, Inc. generates revenue through multiple streams, including tuition fees from training and certification programs offered to healthcare professionals, consultation fees for personalized care strategy development, and sales of educational materials and resources related to terminal care. Additionally, the company may partner with healthcare institutions and organizations to provide tailored training solutions, earning revenue through service contracts. Grants and funding from healthcare foundations and government programs aimed at improving palliative care practices also contribute to the company's financial sustainability.

Terminalcare Support Institute, Inc. Financial Statement Overview

Summary
The company shows solid revenue growth and stable gross margins. However, declining net profit margins and return on equity indicate challenges in profitability. The balance sheet is robust but rising debt levels require caution. Cash flow management, especially regarding capital expenditures, is crucial for financial health.
Income Statement
75
Positive
The company has demonstrated consistent revenue growth over the years, with a notable increase from 2023 to 2024. Gross profit margins have remained stable, indicating effective cost management. However, net profit margins have slightly decreased, which may suggest rising expenses or other cost pressures. EBIT and EBITDA margins show operational efficiency, but there is room for improvement in profitability.
Balance Sheet
70
Positive
The balance sheet reflects a moderate debt-to-equity ratio, indicating a balanced approach to leverage. The equity ratio is healthy, suggesting a strong asset base relative to liabilities. However, the increase in total debt over the years could pose a risk if not managed carefully. Return on equity has decreased, highlighting a need for improved profitability to enhance shareholder returns.
Cash Flow
60
Neutral
Operating cash flow has been positive, supporting the company's operational needs. However, free cash flow has been negative in recent years due to high capital expenditures, which could limit financial flexibility. The operating cash flow to net income ratio is strong, indicating efficient cash generation from operations. The company needs to manage its capital expenditures to improve free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.78B4.71B4.25B4.10B3.40B2.93B
Gross Profit652.76M664.67M646.76M685.84M599.50M464.84M
EBITDA277.80M321.42M300.83M334.75M284.93M237.34M
Net Income83.49M113.77M126.67M157.54M138.03M102.29M
Balance Sheet
Total Assets5.32B4.80B4.09B3.03B2.88B2.06B
Cash, Cash Equivalents and Short-Term Investments887.13M1.13B1.38B1.09B874.72M411.85M
Total Debt3.26B2.81B2.26B1.34B1.43B1.44B
Total Liabilities4.00B3.49B2.90B1.95B1.95B1.82B
Stockholders Equity1.32B1.31B1.19B1.08B927.37M237.34M
Cash Flow
Free Cash Flow0.00-797.40M-597.43M303.05M-57.27M51.51M
Operating Cash Flow0.00304.51M238.18M812.73M462.19M124.89M
Investing Cash Flow0.00-1.10B-836.33M-510.68M-523.54M-74.58M
Financing Cash Flow0.00545.64M892.46M-90.11M523.02M-56.64M

Terminalcare Support Institute, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price821.00
Price Trends
50DMA
844.74
Negative
100DMA
832.07
Negative
200DMA
832.78
Negative
Market Momentum
MACD
-7.42
Positive
RSI
38.42
Neutral
STOCH
3.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7362, the sentiment is Negative. The current price of 821 is below the 20-day moving average (MA) of 840.25, below the 50-day MA of 844.74, and below the 200-day MA of 832.78, indicating a bearish trend. The MACD of -7.42 indicates Positive momentum. The RSI at 38.42 is Neutral, neither overbought nor oversold. The STOCH value of 3.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7362.

Terminalcare Support Institute, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
¥3.04B7.502.61%5.37%-9.33%
75
Outperform
¥3.04B11.582.53%-3.06%-38.56%
74
Outperform
¥9.13B12.981.59%18.30%37.13%
70
Neutral
¥11.42B21.151.13%20.37%-5.97%
68
Neutral
¥3.07B10.542.73%4.76%134.83%
64
Neutral
¥1.25B14.719.76%-10.10%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7362
Terminalcare Support Institute, Inc.
815.00
-57.00
-6.54%
JP:2425
Care Service Co., Ltd.
791.00
-31.86
-3.87%
JP:7061
Japan Hospice Holdings Inc.
1,332.00
-82.47
-5.83%
JP:7129
Miahelsa Holdings Corporation
1,097.00
54.21
5.20%
JP:7133
HYUGA PRIMARY CARE Co.,Ltd.
1,255.00
108.47
9.46%
JP:9220
FB CARE SERVICE CO.,LTD.
1,222.00
329.04
36.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 30, 2025